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Myxoid soft-tissue sarcomas represent a heterogeneous group of mesenchymal tumors characterized by a predominantly myxoid
matrix, including myxoid liposarcoma (MLS), low-grade ﬁbromyxoid sarcoma (LGFMS), extraskeletal myxoid chondrosarcoma
(EMC), myxoﬁbrosarcoma, myxoinﬂammatory ﬁbroblastic sarcoma (MIFS), and myxoid dermatoﬁbrosarcoma protuberans
(DFSP). Cytogenetic and molecular genetic analyses have shown that many of these sarcomas are characterized by recurrent
chromosomal translocations resulting in highly speciﬁc fusion genes (e.g., FUS-DDIT3 in MLS, FUS-CREB3L2 in LGFMS,
EWSR1-NR4A3 in EMC, and COL1A1-PDGFB in myxoid DFSP). Moreover, recent molecular analysis has demonstrated a
translocation t(1;10)(p22;q24) resulting in transcriptional upregulation of FGF8 and NPM3 in MIFS. Most recently, the presence
of TGFBR3 and MGEA5 rearrangements has been identiﬁed in a subset of MIFS. These genetic alterations can be utilized as an
adjunct in diagnostically challenging cases. In contrast, most myxoﬁbrosarcomas have complex karyotypes lacking speciﬁc genetic
alterations. This paper focuses on the cytogenetic and molecular genetic ﬁndings of myxoid soft-tissue sarcomas as well as their
clinicopathological characteristics.
1.Introduction
Myxoid soft-tissue sarcomas encompass a heterogeneous
group of rare tumors characterized by a marked abundance
of mucoid/myxoid extracellular matrix. The main clinico-
pathological entities in this group are myxoid liposarcoma,
low-grade ﬁbromyxoid sarcoma, extraskeletal myxoid chon-
drosarcoma, myxoﬁbrosarcoma, myxoinﬂammatory ﬁbrob-
lastic sarcoma, and myxoid dermatoﬁbrosarcoma protuber-
ans [1–4]. The correct classiﬁcation of these sarcomas is
important because of their distinct biological behaviors and
potentially diﬀerent treatments. However, it is often diﬃcult
tosetapartmanyofthesesarcomasduetooverlapping histo-
logical features and lack of a distinct immunohistochemical
proﬁle. Moreover, the use of core needle biopsies to diagnose
these sarcomas has become increasingly common, and this
shift has created additional challenges.
Cytogenetic and molecular genetic assays are routinely
used for diagnostic and prognostic purposes in molec-
ular pathology laboratories [5]. Many of myxoid soft-
tissue sarcomas are characterized by recurrent chromosomal
translocations resulting in highly speciﬁc fusion genes [6, 7].
Advances in knowledge of the genetics of these sarcomas are
leading to more accurate diagnosis. This paper reviews the
cytogenetic and molecular genetic ﬁndings in these sarcoma
typesandtheirrelationshipwithclinicopathologicalfeatures.
The consistent genetic alterations are summarized in Table 1.
2.Approaches tothe Geneticsof
Soft-Tissue Sarcomas
Conventional karyotyping is the most comprehensive
method for spotting the various translocations and other
structural or numerical aberrations. It is dependent on the
availability of fresh, sterile tumor tissue, the success of tumor
cell growth in culture, and quality of metaphase cell prepara-
tions. When dividing cells are not available for cytogenetic
studies, molecular approaches such as ﬂuorescence in situ
hybridization (FISH), comparative genomic hybridization
(CGH), reverse transcriptase-polymerase chain reaction
(RT-PCR), or gene expression microarray can be used to
evaluate genetic alterations.2 Genetics Research International
Table 1: Chromosomal alterations and related molecular events in myxoid soft-tissue sarcomas.
Tumor type Chromosomal alteration Molecular event Prevalence
Myxoid/round cell liposarcoma t(12;16)(q13;p11) FUS-DDIT3 >90%
t(12;22)(q13;q12) EWSR1-DDIT3 <5%
Low-grade ﬁbromyxoid sarcoma t(7;16)(q32–34;p11) FUS-CREB3L2 >95%
t(11;16)(p11;p11) FUS-CREB3L1 <5%
Extraskeletal myxoid chondrosarcoma
t(9;22)(q22;q12) EWSR1-NR4A3 75%
t(9;17)(q22;q11) TAF15-NR4A3 15%
t(9;15)(q22;q21) TCF12-NR4A3 <1%
t(3;9)(q12;q22) TFG-NR4A3 <1%
Myxoﬁbrosarcoma Complex karyotype Not known Not applicable
Myxoinﬂammatory ﬁbroblastic sarcoma t(1;10)(p22;q24) Deregulation of FGF8 and NPM3 Not applicable
Rearrangement of TGFBR3 and MGEA5 Not applicable
Myxoid dermatoﬁbrosarcoma protuberans t(17;22)(q22;q13)∗ COL1A1-PDGFB >90%
∗Rearrangement also frequently seen as a ring chromosome.
FISH is the most helpful method for identifying speciﬁc
gene rearrangements. It is more adaptable to formalin-
ﬁxed, paraﬃn-embedded tissues although imprint slides are
preferred. Interphase FISH is particularly useful to assess
intratumoral genetic heterogeneity as long as adequate com-
binationofprobesareused.FISHprobesarereadilyavailable
for a variety of relevant gene targets, including DDIT3
(12q13), FUS (16p11), EWSR1 (22q12), FKHR (13q14), SYT
(18q11.2), and ALK (2p23) (Abbott Molecular Inc., Des
Plaines, Ill, USA). It has been realized that FISH is a valuable
adjunct in the diagnosis of myxoid soft-tissue tumors [8].
CGH is a method for genome-wide analysis of DNA se-
quence copy number in a single experiment. It maps the or-
igins of ampliﬁed and deleted DNA sequences on normal
chromosomes, thereby highlighting regions harboring po-
tential oncogenes and tumor suppressor genes. However,
CGH cannot detect rearrangements such as balanced trans-
locations or inversions. Recently, a higher resolution version
of CGH, so-called array CGH, has been made available. A
distinct advantage of array CGH is the ability to directly map
the copy number changes to the genome sequence. Similar
to array CGH, single nucleotide polymorphism (SNP) array
is capable of identifying small regions of chromosomal gains
and losses at a high resolution. Also, SNP array can provide
information regarding loss of hetero-zygosity.
RT-PCR is the most sensitive method to detect small
numbers of translocation-bearing cells that are mixed within
a tissue consisting of largely nonneoplastic cells. Sensitivity
levels of 1 in a 100,000 cells are typically achieved. It may be
suitable for the detection or monitoring of minimal residual
disease [9]. However, the diagnostic success rate is variable
and dependent on multiple factors. First, RNA quality may
be inadequate because of RNA degradation. The second
impediment of this methodology is the high risk of reagent
contamination, mainly with PCR products, particularly in
small laboratory spaces.
Microarray is a method for genome-wide monitoring of
gene expression in a single experiment. A variety of commer-
cial and noncommercial platforms can be used to perform
global gene expression proﬁling. It is hoped that application
of this technology will aﬀord increased understanding of
sarcoma biology and facilitate the development of new
diagnostic markers and therapeutic agents [10–12].
Approximatelyone-thirdofallsoftissuesarcomasexhibit
a nonrandom chromosomal translocation. In addition, a
subset of soft-tissue tumors carries speciﬁc oncogenic muta-
tions (e.g., KIT or PDGFRA mutations in gastrointestinal
stromal tumor). FISH and RT-PCR are commonly applied
for the detection of speciﬁc genetic alterations in the
diﬀerential diagnosis of soft-tissue sarcomas.
3. MyxoidLiposarcoma
The working group of the World Health Organization
(WHO) for classiﬁcation of tumors of soft-tissue and bone
combined myxoid and round cell liposarcomas under myx-
oid liposarcoma (MLS) [13]. MLS is the second most com-
mon subtype of liposarcoma, representing approximately
one-third of all liposarcomas. MLS occurs predominantly in
the deep soft-tissues of lower extremities and has a peak inci-
dence in the fourth and ﬁfth decades of life with no gender
predilection. Pure MLS is considered low-grade and has a 5-
year survival rate of 90% [14]. In contrast, MLS containing a
greater than 5% round cell component is considered high-
grade and has a worse prognosis. The clinical outcome of
multifocal MLS is poor [15]. In contrast to other soft-tissue
sarcomas, MLS tends to metastasize to unusual sites such as
retroperitoneum, opposite extremity, and bone.
Histologically, pure MLS is composed of primitive mes-
enchymal cells in a myxoid matrix, often featuring mucinous
pools (Figure 1(a)). Lipoblasts are most often univacuolated,
small, and tend to cluster around vessels or at the periphery
of the lesion. A delicate plexiform capillary vascular network
is present and provides an important clue for distinguishing
MLS from intramuscular myxoma [16]. A subset of MLS
shows histological progression to hypercellular or round
cell morphology. The round cell areas are characterized by
solid sheets of primitive round cells with a high nuclear/
cytoplasmic ratio and a prominent nucleolus. Pure round
cell liposarcoma is extremely rare and may be confused withGenetics Research International 3
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Figure 1: (a) Myxoid liposarcoma with a myxoid background
containing a delicate arborizing capillary vascular network, small
uniform mesenchymal cells, and lipoblasts. (b) G-banded kary-
otype showing a 12;16 translocation as the sole aberration. (c)
Fluorescence in situ hybridization analysis using a DDIT3 (12q13)
break-apart probe shows a split of the orange and green signals,
indicating a disruption of the DDIT3 locus.
other round cell sarcomas such as Ewing sarcoma/primitive
neuroectodermal tumor, rhabdomyosarcoma, and poorly
diﬀerentiated synovial sarcoma.
MLS is characterized by a recurrent translocation t(12;
16)(q13;p11)inmorethan90%ofcases(Figure1(b)),which
fuses the 5  portion of the FUS gene on chromosome 16 with
entire reading frame of the DDIT3 gene on chromosome 12
[17–19]. A small percentage of cases carry a variant trans-
location t(12;22)(q13;q12) resulting in an EWSR1-DDIT3
fusion gene [15, 20–28]. The presence of these translocations
and molecular alterations is highly sensitive and speciﬁc for
MLS. Therefore, cytogenetics is an excellent analytic method
for the initial workup of a suspectedMLS. FISH and RT-PCR
can also be used to provide support for the diagnosis of MLS
(Figure 1(c))[ 8, 29–32]. In addition, several nonrandom
secondaryalterationshavebeenidentiﬁed,including6qdele-
tion, isochromosome 7q10, trisomy 8, and unbalanced 1;16
translocation [17, 24, 33–35]. Conventional and array CGH
studies have shown gains of 8p21–23, 8q, and 13q [36–38].
To date, 12 FUS-DDIT3andfourEWSR1-DDIT3variants
of fusion transcripts have been described in MLS [22, 26, 28,
39, 40]. Most cases of MLS are one of three diﬀerent FUS-
DDIT3 fusion transcript types, including varying portions of
FUS.TheFUS-DDIT3fusiontranscript typedoes notappear
to have a signiﬁcant impact on clinical outcome [22, 26].
On the other hand, Suzuki et al. [28] reported that MLS
with a type 1 EWSR1-DDIT3 fusion transcript may show
more favorable clinical behavior than MLS with other types
of fusion transcripts. Interestingly, clinical data suggest that
the fusion transcript type may inﬂuence response to therapy
with trabectedin [41].
Several receptor tyrosine kinases (RTKs) are highly
expressed in MLS, including RET, MET, and IGF1R [42, 43].
These RTKs promote cell survival and cell proliferation
through the PI3K/AKT and the Ras-Raf-ERK/MAPK path-
ways [42]. Recently, Barretina et al. [44] demonstrated that
mutation of PIK3CA, encoding the catalytic subunit of PI3K,
is associated with AKT activation and poor clinical outcome.
AKT activation functions as a master switch to generate a
plethora of intracellular signals and intracellular responses
andismorefrequentintheroundcellvariant[43].Ithasalso
been shown that the NF-κB pathway is highly active in MLS
[40]. Moreover, G¨ oransson et al. [45] showed that NF-κBi s
a major factor controlling IL8 transcription in FUS-DDIT3-
expressing cells. NF-κB is an inducible cellular transcription
factor that regulates a variety of cellular genes, including
those involved in immune regulation, inﬂammation, cell
survival, and cell proliferation. These ﬁndings will help to
developnewpotentialtherapeuticstrategiesforMLSpatients
with advanced disease.
4. Low-Grade FibromyxoidSarcoma
Low-grade ﬁbromyxoid sarcoma (LGFMS), ﬁrst described
by Evans [46] in 1987, is a rare but distinctive ﬁbromyxoid
variant of ﬁbrosarcoma. It includes the tumor originally
designed as hyalinizing spindle cell tumor with giant rosettes
[47]. LGFMS occurs primarily in young to middle-aged
adults with a male predominance, but this tumor may aﬀect
children [48, 49]. LGFMS typically presents as a slowly
growing, painless mass in the deep soft-tissues of lower
extremities or trunk. Local recurrence and metastatic rates
are 9%–21% and 6%–27%, respectively [49, 50]. The overall
prognosis for superﬁcial LGFMS appears to be better than
that for deep LGFMS [48].
Histologically, LGFMS shows alternating ﬁbrous and
myxoid areas with bland spindle-shaped cells arranged in
a whorled pattern (Figure 2). Cellularity is variable but gen-
erally low and mitoses are scarce. There is often a prominent4 Genetics Research International
network of branching capillary-sized blood vessels rem-
iniscent of myxoid liposarcoma. Approximately 40% of
cases have giant collagen rosettes characterized by a central
zone of eosinophilic collagen surrounded by a palisade of
round to oval tumor cells [13]. This variant was originally
termed hyalinizing spindle cell tumor with giant rosettes
[47]. Immunohistochemically, the tumor cells are diﬀusely
positive for vimentin and focally for epithelial membrane
antigen (EMA) [48, 50]. Immunostains for S-100 protein,
desmin, and CD34 are typically negative.
LGFMS is characterized by a recurrent balanced translo-
cation t(7;16)(q34;p11) resulting in an FUS-CREB3L2
fusion gene [50–53]. This same translocation was identiﬁed
in cases of hyalinizing spindle cell tumor with giant rosettes
[54, 55], suggesting a pathogenetic link between these two
entities. A small percentage of cases carry a variant translo-
cation t(11;16)(p11;p11) leading to a fusion of the FUS
and CREB3L1 genes [50, 53]. Interestingly, supernumerary
ring chromosomes have been observed as the sole anomaly
in a subset of LGFMS [52, 56, 57]. FISH and CGH studies
have demonstrated that ring chromosomes are composed of
material from chromosomes 7 and 16 [56, 57]. Bartuma et
al. [57] showed that the FUS-CREB3L2 fusion gene can be
present in ring chromosomes.
The breakpoints in the fusion transcripts are mostly at
e x o n6o r7o fFUS a n de x o n5o fCREB3L2 or CREB3L1
[50–53, 58]. CREB3L2 is a member of CREB3 family of
transcription factors and contains a basic DNA-binding and
leucine zipper dimerization domain, highly similar to that in
CREB3L1. Panagopoulos et al. [59] suggested that the FUS-
CREB3L2 fusion protein is a more potent transcriptional
activator than the native CREB3L2 and may contribute to
the pathogenesis of LGFMS through the deregulation of its
target genes. The molecular variability of fusion transcripts
in LGFMS does not appear to have a signiﬁcant impact on
microscopic appearances or clinical outcome [53].
5. ExtraskeletalMyxoidChondrosarcoma
Extraskeletal myxoid chondrosarcoma (EMC) is categorized
by the WHO as a tumor of uncertain diﬀerentiation, because
there is a paucity of convincing evidence of cartilaginous
diﬀerentiation [13]. Most EMCs arise in the deep soft-tissues
of the proximal extremities and limb girdles, especially the
thigh and popliteal fossa, similar to MLS. EMC has a peak
incidence in the ﬁfth and six decades of life with a male
predominance. Only a few cases have been encountered in
children and adolescents [60–62]. Patients typically present
with a slowly growing mass that causes pain or tenderness
in approximately one-third of cases [16]. Local recurrence
and metastatic rates are 48% and 46%, respectively [61].
EMC has a 10-year survival rate of 63%–88%, but a 10-
year disease-free survival is much lower, ranging from 14%
to 36% [61, 63–66]. Large tumor size (especially >10cm),
advanced age, and proximal tumor location appear to be
poor prognostic factors in EMC [61, 63, 67].
Histologically, EMC is characterized by multinodular
growth of a cord-like or lace-like arrangement of round or
slightly elongated cells in an abundant myxoid matrix (Fig-
Figure 2: Low-grade ﬁbromyxoid sarcoma with alternating ﬁbrous
and myxoid areas.
Figure 3: Extraskeletal myxoid chondrosarcoma with an abundant
myxoid matrix containing round or slightly elongated cells with
small hyperchromatic nuclei.
ure3).Thetumorcellsha v esmallh yperchromaticnucleiand
a narrow rim of deeply eosinophilic cytoplasm. Occasional
cells show cytoplasmic vacuolization [16]. Mitotic ﬁgures are
rare in most cases. In contrast to the bland-looking or low-
grade morphology, cellular or high-grade EMC has also been
described [61, 68, 69]. Some authors have suggested that the
cellularorhigh-gradeEMCislikelytohaveaworseprognosis
than conventional EMC [63, 68, 70] although its prognostic
signiﬁcance has not yet been established [67]. Immunohisto-
chemically, vimentin is the only marker consistently positive
in EMC. S-100 protein is expressed in approximately 30%
of cases [67], often with focal and weak immunoreactivity.
Onlyasmallpercentageofcasesmayshowscatteredcellsthat
are EMA positive [67]. Recent immunohistochemical and
ultrastructural studies have demonstrated that some EMCs
may have neuroendocrine diﬀerentiation [63, 69, 71].
EMC is characterized by a recurrent translocation t(9;
22)(q22;q12) in approximately 75% of cases, which fuses
the EWSR1 gene on 22q12 with the NR4A3 gene on 9q22
[72–78]. A second variant translocation, t(9;17)(q22;q11),
h a sb e e nd e t e c t e di na p p r o x i m a t e l y1 5 %o fE M Ca n dr e s u l t s
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additionalvarianttranslocations,t(9;15)(q22;q21)resulting
in a TCF12-NR4A3 fusion gene and t(3;9)(q12;q22) result-
ing in a TFG-NR4A3 fusion gene, have also been identiﬁed,
each only in a single case [83, 84]. Because these fusion
genes have not yet been described in any other tumor type,
they represent useful diagnostic markers. Moreover, several
nonrandom secondary alterations have been identiﬁed in
approximately 50% of cytogenetically analyzed cases, includ-
ing gain of 1q and trisomy for chromosomes 7, 8, 12, and 19
[77, 78]. The biological signiﬁcance of these chromosomal
alterations remains unknown.
Two main EWSR1-NR4A3 fusion transcript types have
been reported for the t(9;22)(q22;q12) in EMC [69, 77, 78].
The most common fusion transcript contains exon 12 of
EWSR1 fused to exon 3 of NR4A3 (type 1), whereas exon
7o fEWSR1 is fused to exon 2 of NR4A3 in the type 2
fusion transcript. In the TAF15-NR4A3 fusion transcript,
exon 6 of TAF15 is fused exclusively to exon 3 of NR4A3 [77].
NR4A3 is a member of NR4A subfamily within the nuclear
receptorsuperfamilyandcontainsazincﬁngerDNA-binding
domain. The EWSR1-NR4A3 fusion protein is thought to
function as a potent transcriptional activator for NR4A3-
target genes [85, 86]. It has also been shown that the TAF15-
NR4A3 fusion protein functions a strong transcriptional
activator [87]. It is unclear whether the fusion transcript
type is associated with particular morphological features or
clinical outcome.
Gene expression proﬁling studies of EMC have revealed
overexpression of the CHI3L1, METTL1, RELB, MYB, NMB,
DKK1, DNER, CLCN3, DEF6, NDRG2,a n dPPARG genes
[78, 88, 89]. In addition, several genes encoding neural-
neuroendocrine markers have been expressed, including
SCG2, NEF3, GFAP, GAD2, ENO2, SYP, CHGA, NEF3,a n d
INSM1 [78, 88]. CHI3L1 encodes a glycoprotein member of
the glycosyl hydrolase 18 family, which is secreted by acti-
vated chondrocytes, macrophages, neutrophils, and synovial
cells. Sj¨ ogren et al. [78] suggested that CHI3L1 may be useful
as a serum marker monitoring disease progression in EMC
patients. NMB is a member of bombesin-related peptide
family in mammals and a secreted protein involved in stim-
ulation of smooth muscle contraction [90]. Subramanian
et al. [88] suggested that NMB may prove to be a serological
marker of EMC recurrence. DKK1 encodes a protein that
is a member of the dickkopf family. DKK1 is involved in
embryonic development through its inhibition of the WNT
signalingpathway.BecauseDKK1isasecretedprotein,itmay
serve as a prognostic marker for evaluation of EMC. PPARG
encodes a member of the peroxisome proliferator-activated
receptor subfamily of nuclear receptors. PPARG is known as
a regulator of adipocytic diﬀerentiation [91]. Interestingly,
Filion et al. [89] demonstrated that PPARG is the ﬁrst direct
transcriptional target of the EWSR1-NR4A3 fusion protein.
These ﬁndings will lead to the development of molecularly
targeted therapies for patients with advanced EMC.
6. Myxoﬁbrosarcoma
Myxoﬁbrosarcoma, formerly known as myxoid malignant
ﬁbrous histiocytoma (MFH), is now deﬁned as a distinct
histological entity [13]. It is one of the most common soft-
tissue sarcomas in elderly patients. Most myxoﬁbrosarcomas
arise in the dermal and subcutaneous tissues of the limbs
(especially lower limbs) and limb girdles. Myxoﬁbrosarcoma
has a peak incidence in the sixth to eighth decades of life
with a slight male predominance. Patients typically present
with a slowly growing, painless mass. Recently, an epithelioid
variant of myxoﬁbrosarcoma with an aggressive course has
been described [92].
Gradingofmyxoﬁbrosarcomaissomewhatcontroversial.
Myxoﬁbrosarcoma has been subdivided into three or four
grades based on the degree of cellularity, nuclear pleo-
morphism, and mitotic activity [93, 94]. Local recurrences
occur in up to 50% to 60% of cases [93–95], irrespective
ofhistologicalgrade.Whereaslow-grademyxoﬁbrosarcomas
usually do not metastasize, intermediate and high-grade
lesionsmaydevelopmetastasesinapproximately16%to38%
of cases [93–95]. Importantly, low-grade myxoﬁbrosarcomas
may become higher grade in subsequent recurrences and
acquire metastatic potential. The overall 5-year survival rate
is 60%–70% [13].
Histologically, myxoﬁbrosarcoma is characterized by
multinodular growth of spindle or stellate-shaped cells
within variably myxoid stroma containing elongated, curvi-
linear blood vessels (Figure 4) .T h et u m o rc e l l sh a v e
slightly eosinophilic cytoplasm and mildly atypical, hyper-
chromatic nuclei. Vacuolated cells with cytoplasmic acid
mucin, mimicking lipoblasts, are also seen [13]. Mitotic
ﬁgures are rare in low-grade lesions. In contrast, high-grade
myxoﬁbrosarcomas are composed of solid sheets and
fascicles of atypical spindled and pleomorphic tumor cells
with hemorrhagic and necrotic areas. Bizarre, multinu-
cleatedgiantcellsarealsooccasionallyfound.Mitoticﬁgures,
including abnormal mitoses, are frequent. At least focally,
however, areas of a lower grade neoplasm with a prominent
myxoid matrix are present [13]. Intermediate-grade myxo-
ﬁbrosarcomas are more cellular than low-grade lesions and
often contain minute solid areas showing ﬂank pleomor-
phism. Immunohistochemically, the tumor cells are diﬀusely
positive for vimentin and occasionally for muscle speciﬁc
actin and α-smooth muscle actin, suggestive of focal myo-
ﬁbroblastic diﬀerentiation.
Data on the cytogenetics and molecular genetics of myx-
oﬁbrosarcoma are diﬃcult to evaluate, because the diagnos-
tic criteria for this tumor have changed with time. In general,
myxoﬁbrosarcomas are associated with highly complex
karyotypes lacking speciﬁc structural aberrations [96–98].
The only recurrent gain involves chromosome 7, whereas
losses primarily aﬀect chromosomes 1, 3, 5, 6, 10, 12, 16,
17, and 19 [7]. The presence of ring chromosomes has been
described in some cases of low-grade myxoﬁbrosarcoma
(or myxoid MFH) [98–100]. In addition, homogeneously
staining regions, double minutes, and marker chromosomes
have been found. Recently, Willems et al. [98] proposed the
concept of progression of myxoﬁbrosarcoma as a multistep
genetic process ruled by genetic instability.
A conventional CGH study of 22 myxoﬁbrosarcomas
showed gains of 19p and 19q, losses of 1q, 2q, 3p, 4q, 10q,
11q, and 13q, and high-level ampliﬁcations of the central6 Genetics Research International
regions of chromosome 1, 5p, and 20q [101]. Interestingly,
gain of 5p and loss of 4q are not observed in low-grade
myxoﬁbrosarcomas as opposed to higher grade neoplasms,
suggesting that these aberrations are late events in the onco-
genesisofmyxoﬁbrosarcoma.Inaddition,arrayCGHstudies
showed gains of 7p21-22, 7q31–35, and 12q15–21 and
losses of 10p13-14, 10q25-26, and 13q14–34 [38, 102, 103].
These ﬁndings suggest that loss of chromosome 13q is the
most frequent genomic imbalance in myxoﬁbrosarcoma,
leading to inactivation of the RB pathway.
Recently, Lee et al. [103] reported that MET is expressed
in approximately two-third of cases and its overexpression
is highly related to deep location, higher grades, and more
advanced stages. The authors suggested that MET may
represent a target of choice to develop novel therapeutic
strategies for myxoﬁbrosarcoma.
A recent gene expression analysis has shown that the
WISP2, GPR64,a n dTNXB genes are upregulated in myx-
oﬁbrosarcoma compared with other spindle cell and pleo-
morphic sarcomas [104]. WISP2 encodes a member of
the WNT1 inducible signaling pathway protein subfamily,
which belongs to the connective tissue growth factor family.
WISP2 is a secreted protein involved in several important
human diseases or conditions that are marked by aberrant
cell proliferation and migration [105]. GPR64 is a highly
conserved, tissue-speciﬁc, seven-transmembrane receptor of
the human epididymis [106]. TNXB encodes a member
of the tenascin family of extracellular matrix glycopro-
teins. TNXB is thought to function in matrix maturation
during wound healing, and its deﬁciency is associated
with the connective tissue disorder Ehlers-Danlos syndrome
[107]. Nakayama et al. [104] suggested that these genes
may serve as novel diagnostic markers for myxoﬁbrosar-
coma. Most recently, Barretina et al. [44] demonstrated
that NF1 is mutated or deleted in 10.5% of myxoﬁbro-
sarcomas.
7. Myxoinﬂammatory FibroblasticSarcoma
Myxoinﬂammatoryﬁbroblasticsarcoma(MIFS),alsoknown
as inﬂammatory myxohyaline tumor of the distal extremities
with virocyte or Reed-Sternberg-like cells, is a recently
described soft-tissue tumor entity [108, 109]. MIFS occurs
predominantly in the subcutaneous tissues of distal extrem-
ities and has a peak incidence in the fourth and ﬁfth
decades of life with no gender predilection. Patients typically
present with a slowly growing, painless, ill-deﬁned mass.
The preoperative diagnosis in most cases is benign and may
include tenosynovitis, ganglion cyst, and giant cell tumor of
tendon sheath [13]. Local recurrence and metastatic rates are
31.3% and 3.1%, respectively [110].
Histologically, MIFS is multinodular, poorly delineated,
and characterized by a prominent myxoid matrix contain-
ing numerous inﬂammatory cells, including lymphocytes,
plasma cells, neutrophils, and eosinophils [109]. Germinal
centersareoccasionallyencountered.Neoplasticcellsinclude
spindle-shaped and epithelioid cells with mild to moder-
ate nuclear atypia, large polygonal and bizarre ganglion-
like cells, Reed-Sternberg-like cells with huge inclusion-like
Figure 4: Myxoﬁbrosarcoma with a myxoid stroma containing
spindleorstellate-shapedcellswithmildlyatypical,hyperchromatic
nuclei.
Figure 5: Myxoinﬂammatory ﬁbroblastic sarcoma with a myx-
oid background containing spindle-shaped and epithelioid cells,
inﬂammatory cells, and pseudolipoblasts.
nucleoli, and multivacuolated lipoblast-like cells (Figure 5).
Hemosiderin deposition may be conspicuous. Mitotic activ-
i t yi su s u a l l yl o w ,a n dn e c r o s i si sr a r e l yp r e s e n t .I m m u n o -
histochemically, the tumor cells are diﬀusely positive for
vimentin and focally for CD68 and CD34 [16]. Occasional
cases may show scattered cells that stain for cytokeratin or
α-smooth muscle actin. Immunostains for S-100 protein,
HMB-45, desmin, EMA, leukocyte common antigen, CD15,
and CD30 are typically negative.
Cytogenetic and molecular cytogenetic studies have
identiﬁed the frequent presence of a balanced or unbalanced
t(1;10)(p22;q24) translocation and ring chromosomes con-
taining ampliﬁed material from the 3p11-12 region in MIFS
[111–113]. A balanced translocation, t(2;6)(q31;p21.3), has
also been described as the sole anomaly in a single case
[114]. Most recently, Antonescu et al. [115] demonstrated
the presence of TGFBR3 (1p22) and MGEA5 (10q24) gene
rearrangements by FISH in a subset of MIFS. It is of interest
thatthet(1;10)translocationandthesegenerearrangements
have also been identiﬁed in hemosiderotic ﬁbrolipomatous
tumor (HFLT) [113, 115–117]. These ﬁndings suggest thatGenetics Research International 7
MIFS and HFLT may represent diﬀerent morphologic vari-
ants of the same entity.
Conventional and array CGH studies showed ampliﬁ-
cation of 3p11-12 [113, 118]. Notably, Hallor et al. [113]
demonstrated that 3p11-12 ampliﬁcation is associated with
an increased expression of VGLL3 and CHMP2B. VGLL3
encodes a protein that is a cofactor of transcription factors
of the TEAD family. It has also been shown that VGLL3 is
ampliﬁed and overexpressed in myxoﬁbrosarcoma, undiﬀer-
entiated pleomorphic sarcoma, and dediﬀerentiated liposar-
coma [119]. These ﬁndings strongly suggest that VGLL3 is
the main target of 3p11-12 ampliﬁcation and this genetic
event plays an important role in the development and
progression of certain subsets of soft-tissue sarcomas.
A recent gene expression analysis has shown that the
FGF8 and NPM3 genes are upregulated in the t(1;10) -
positive tumors compared with tumors without such a
translocation[113].ThesetwogenesdownstreamofMGEA5
have been mapped to 10q24. FGF8, a member of the
ﬁbroblast growth factor family, is a secreted heparin-binding
protein, which has transforming potential. FGF8 is widely
expressed during embryonic development. Overexpression
of FGF8 has been shown to increase tumor growth and
angiogenesis [120]. Hallor et al. [113] suggested that dereg-
ulation of FGF8 may constitute an important event in the
development of a subset of MIFS.
8. MyxoidDermatoﬁbrosarcoma Protuberans
Myxoid dermatoﬁbrosarcoma protuberans (DFSP) is a rare
but distinctive variant of DFSP with a prominent myxoid
matrix. Clinically, myxoid DFSP is similar to typical DFSP
[121–123]. DFSP occurs primarily young to middle-aged
adults with a male predominance, but this tumor may aﬀect
children, including congenital occurrence [124]. It typically
presents as a slowly growing, plaque-like or small nodular
lesion. The most common location is the trunk, followed by
thelimbsandheadandneck.Localrecurrenceandmetastatic
rates are 0%–52% and 0%–1.7%, respectively [125]. The
overall prognosis of typical DFSP is excellent if completely
excised with negative microscopic margins. Reimann and
Fletcher [122] stated that myxoid DFSP appears to have a
similarly good prognosis. Recognition of this DFSP variant
is important to avoid misdiagnosis of more or less aggressive
myxoid soft-tissue tumors.
Histologically, myxoid DFSP is characterized by a sheet-
like to vaguely lobular proliferation of bland spindle cells
in an abundant myxoid stroma (Figure 6). The tumor
cells have slightly eosinophilic cytoplasm and stellate to
oval nuclei with indistinct nucleoli. Branching, thin-walled
blood vessels are frequently present. All cases display at
least focally a strikingly inﬁltrative growth pattern, with
trapping of subcutaneous adipose tissue in the characteristic
honeycomb manner also observed in typical DFSP [122].
Mitotic activity is usually low. Immunohistochemically, the
tumor cells are diﬀusely positive for vimentin and CD34.
Immunostains for S-100 protein, desmin, muscle speciﬁc
actin, α-smooth muscle actin, cytokeratin, and EMA are typ-
ically negative. Apolipoprotein D (APOD) has been found
Figure 6: Typical example of a myxoid dermatoﬁbrosarcoma pro-
tuberans.
to be highly expressed in DFSP and its histological variants
[126].
DFSP is characterized by an unbalanced translocation
t(17;22)(q22;q13), which fuses the COL1A1 gene on 17q21-
22 with the PDGFB gene on 22q13 [127–130]. The same
molecular event is also seen in supernumerary ring chromo-
somesderivedfromthet(17;22)[129,130].Identicalgenetic
changes have also been shown in the histological variants,
including myxoid DFSP [123], pigmented DFSP (Bednar
tumor) [131], Granular cell DFSP [132], juvenile variant of
DFSP (giant cell ﬁbroblastoma) [128], and ﬁbrosarcomatous
variant of DFSP [133, 134]. Other rare translocations,
including t(X;7), t(2;7), t(9;22), and t(5;8), have also
been described [135–138]. Moreover, several secondary
nonrandom alterations have been identiﬁed, including tri-
somy 5 and trisomy 8 [130]. The clinical and biological
implications of these chromosomal alterations are virtually
unknown.
Conventional and array CGH studies showed gain or
high-level ampliﬁcation of 17q and 22q in most cases
[139–141]. DFSP is occasionally misdiagnosed as benign
lesions such as dermatoﬁbroma, leading to improper pri-
mary management. We suggested that CGH may be a
useful diagnostic tool for distinguishing DFSP from der-
matoﬁbroma [140]. The presence of gain in 8q was also
observed [140–142]. Interestingly, FISH and CGH studies
have indicated an association between an increased num-
ber of COL1A1-PDGFB genomic copies and ﬁbrosarco-
matuos transformation in a subset of DFSP [139, 143,
144]. Most recently, Salgado et al. [145] reported that
the majority of DFSP harbor the COL1A1-PDGFB fusion
and FISH should be recommended as a routine diagnostic
tool.
The breakpoint of PDGFB is remarkably constant (exon
2). In contrast, the COL1A1 breakpoint may occur in any
of the exons in the α-helical coding region (exons 6–49).
The most frequently rearranged COL1A1 exons are exon 25,
32, and 47 [146]. PDGFB encodes the β chain of platelet-
derived growth factor. PDGFB is a potent mitogen for8 Genetics Research International
av a r i e t yo fc e l l s[ 147]. COL1A1 encodes the pro-α1 chains
of type I collagen whose triple helix comprises two α1 chains
and one α2 chain. Type I collagen is a major structural
protein found in the extracellular matrix of connective
tissue such as skin, bone, and tendon. The COL1A1-PDGFB
fusionproteinisposttranslationallyprocessedtoafunctional
PDGFB, and results in PDGFB-mediated autocrine and/or
paracrine activation of PDGFRB [128, 148]. Inhibitors of
PDGFRB, such as imatinib mesylate, have been reported to
showclinicalactivityformetastaticorlocallyadvancedDFSP
[149–151]. These results support the concept that DFSP
c e l l sa r ed e p e n d e n to na b e r r a n ta c t i v a t i o no fP D G F R Bf o r
cellular proliferation and survival. No correlation between
the molecular subtype of COL1A1-PDGFB fusion gene
and the clinicopathological features has been established
[146, 152].
Gene expression proﬁling studies of DFSP have revealed
overexpression of the PDGFB, PDGFRB, APOD, SPRY2,
NRP1, EGR2,a n dMEOX1 genes [10, 153]. SPRY2 encodes
a protein belonging to the sprouty family and is involved
in the regulation of the EGF, FGF, and Ras/MAPK sig-
naling pathways. NRP1 is a membrane-bound coreceptor
to a tyrosine kinase receptor for both vascular endothelial
growth factor and semaphorin family members and plays a
role in angiogenesis, cell survival, migration, and invasion.
EGR2 is a transcription factor with three tandem C2H2-
type zinc ﬁngers and plays a role in the PTEN-induced
apoptotic pathway[154]. MEOX1 has been mapped to 17q21
and encodes a member of a subfamily of nonclustered,
diverged, antennapedia—like homeobox—containing genes.
T h eh o m e o b o xg e n e sa r ei n v o l v e di ne a r l ye m b r y o n i c
development and the determination of cell fate. Linn et al.
[153] proposed the possibility that DFSP are derived from
early embryonic mesenchymal cells.
9. Conclusions
Itisimportanttobefamiliarwiththeclinicopathologicaland
molecular genetic features of myxoid soft-tissue sarcomas
for their accurate diagnosis and appropriate treatment. In
our experience, FISH is a valuable ancillary diagnostic tool
for these sarcomas, especially on limited tissue samples.
Novel diagnostic and/or prognostic molecular markers as
well as promising therapeutic targets have gradually been
recognized. In the future, treatment decisions and prognosis
assessment for myxoid soft-tissue sarcomas will increasingly
be based on a combination of histological criteria and
molecular identiﬁcation of genetic alterations indicative of
biological properties.
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